Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition.

Abstract:

BACKGROUND:Activating transcription factor-3 (ATF3) is involved in the complex process of cellular stress response. However, its exact role in cancer is discussed controversially because both tumor suppressive and oncogenic effects have been described. Here we followed-up on our previous observation that inhibition of Hsp90 may increase ATF3 expression and sought to determine the role of ATF3 in colon cancer. METHODS:Regulation of ATF3 was determined in cancer cells using signaling inhibitors and a heat-shock protein-90 (Hsp90) antagonist. Human HCT116 cancer cells were stably transfected with an ATF3-shRNA or a luciferase-shRNA expression plasmid and alterations in cell motility were assessed in migration assays. The impact of ATF3 down-regulation on cancer growth and metastasis were investigated in a subcutaneous tumor model, a model of hepatic tumor growth and in a model of peritoneal carcinomatosis. Human colon cancer tissues were analyzed for ATF3 expression. RESULTS:The results show that therapeutic Hsp90 inhibition substantially up-regulates the expression of ATF3 in various cancer cells, including colon, gastric and pancreatic cancer. This effect was evident both in vitro and in vivo. RNAi mediated knock-down of ATF3 in HCT116 colon cancer cells significantly increased cancer cell migration in vitro. Moreover, in xenogenic mouse models, ATF3 knock-down promoted subcutaneous tumor growth and hepatic metastasis, as well as peritoneal carcinomatosis. Importantly, ATF3 expression was lower in human colon cancer specimens, as compared to corresponding normal surrounding tissues, suggesting that ATF3 may represent a down-regulated tumor suppressor in colon cancer. CONCLUSION:In conclusion, ATF3 down-regulation in colon cancer promotes tumor growth and metastasis. Considering that blocking Hsp90 induces ATF3 expression, Hsp90 inhibition may represent a valid strategy to treat metastatic colon cancer by up-regulating this anti-metastatic transcription factor.

journal_name

BMC Cancer

journal_title

BMC cancer

authors

Hackl C,Lang SA,Moser C,Mori A,Fichtner-Feigl S,Hellerbrand C,Dietmeier W,Schlitt HJ,Geissler EK,Stoeltzing O

doi

10.1186/1471-2407-10-668

subject

Has Abstract

pub_date

2010-12-03 00:00:00

pages

668

issn

1471-2407

pii

1471-2407-10-668

journal_volume

10

pub_type

杂志文章
  • GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study.

    abstract:BACKGROUND:In Europe, gastric cancer remains diagnosed at advanced stage (serosal and/or lymph node involvement). Despite curative management combining perioperative systemic chemotherapy and gastrectomy with D1-D2 lymph node dissection, 5-year survival rates of T3 and/or N + patients remain under 30%. More than 50% of...

    journal_title:BMC cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/1471-2407-14-183

    authors: Glehen O,Passot G,Villeneuve L,Vaudoyer D,Bin-Dorel S,Boschetti G,Piaton E,Garofalo A

    更新日期:2014-03-14 00:00:00

  • Oxidative stress in susceptibility to breast cancer: study in Spanish population.

    abstract:BACKGROUND:Alterations in the redox balance are involved in the origin, promotion and progression of cancer. Inter-individual differences in the oxidative stress regulation can explain a part of the variability in cancer susceptibility.The aim of this study was to evaluate if polymorphisms in genes codifying for the di...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-14-861

    authors: Rodrigues P,de Marco G,Furriol J,Mansego ML,Pineda-Alonso M,Gonzalez-Neira A,Martin-Escudero JC,Benitez J,Lluch A,Chaves FJ,Eroles P

    更新日期:2014-11-21 00:00:00

  • Breast and cervical cancer screening services in Malawi: a systematic review.

    abstract:BACKGROUND:To identify and to assess factors enhancing or hindering the delivery of breast and cervical cancer screening services in Malawi with regard to accessibility, uptake, acceptability and effectiveness. METHODS:Systematic review of published scientific evidence. A search of six bibliographic databases and grey...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-020-07610-w

    authors: Pittalis C,Panteli E,Schouten E,Magongwa I,Gajewski J

    更新日期:2020-11-12 00:00:00

  • Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.

    abstract:BACKGROUND:Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-018-4637-6

    authors: McEvoy AC,Warburton L,Al-Ogaili Z,Celliers L,Calapre L,Pereira MR,Khattak MA,Meniawy TM,Millward M,Ziman M,Gray ES

    更新日期:2018-07-09 00:00:00

  • The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models.

    abstract:BACKGROUND:Lung cancer is the number one cancer killer worldwide. A major drawback in the lung cancer treatment field is the lack of realistic mouse models that replicate the complexity of human malignancy and immune contexture within the tumor microenvironment. Such models are urgently needed. Mutations of the tumor p...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-020-07212-6

    authors: Ramelow J,Brooks CD,Gao L,Almiman AA,Williams TM,Villalona-Calero MA,Duan W

    更新日期:2020-08-08 00:00:00

  • Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer.

    abstract:BACKGROUND:The metastasis-promoting protein S100A4 induces expression of ephrin-A1 and osteopontin in osteosarcoma cell lines. The aim of this study was to investigate S100A4-mediated stimulation of ephrin-A1 and osteopontin in non-small cell lung cancer (NSCLC) cell lines, and to characterize the expression of these b...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-12-333

    authors: Rud AK,Lund-Iversen M,Berge G,Brustugun OT,Solberg SK,Mælandsmo GM,Boye K

    更新日期:2012-08-01 00:00:00

  • Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.

    abstract:BACKGROUND:Metformin is a biguanide oral hypoglycaemic agent commonly used for the treatment of type 2 diabetes mellitus. In addition to its anti-diabetic effect, metformin has also been associated with a reduced risk of cancer incidence of a number of solid tumours, including prostate cancer (PCa). However, the underl...

    journal_title:BMC cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1186/s12885-017-3458-3

    authors: Crawley D,Chandra A,Loda M,Gillett C,Cathcart P,Challacombe B,Cook G,Cahill D,Santa Olalla A,Cahill F,George G,Rudman S,Van Hemelrijck M

    更新日期:2017-07-21 00:00:00

  • Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells.

    abstract:BACKGROUND:Cancer stem cell (CSC) hypothesis has not been well demonstrated by the lack of the most convincing evidence concerning a single cell capable of giving rise to a tumor. The scarcity in quantity and improper approaches for isolation and purification of CSCs have become the major obstacles for great developmen...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-8-135

    authors: Li HZ,Yi TB,Wu ZY

    更新日期:2008-05-14 00:00:00

  • EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.

    abstract:BACKGROUND:Glioblastoma multiforme (GBM) is the most malignant central nervous system tumor. Alkylating agent, temozolomide (TMZ), is currently the first-line chemotherapeutic agent for GBM. However, the sensitivity of GBM cells to TMZ is affected by many factors. And, several clinic trials, including co-administration...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-018-5056-4

    authors: Li L,Huang Y,Gao Y,Shi T,Xu Y,Li H,Hyytiäinen M,Keski-Oja J,Jiang Q,Hu Y,Du Z

    更新日期:2018-12-04 00:00:00

  • Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer.

    abstract:BACKGROUND:Lymphovascular invasion (LBVI) including lymphatic (LVI) and blood (BVI) vessel invasion is a critical step in cancer metastasis. In breast cancer, the optimal detection method of LBVI remains unclear. This research aimed to compare the prognostic value of different assessments of the LVI and BVI in patients...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-14-676

    authors: Gujam FJ,Going JJ,Mohammed ZM,Orange C,Edwards J,McMillan DC

    更新日期:2014-09-18 00:00:00

  • CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension.

    abstract:BACKGROUND:The prognostic variability of thyroid carcinomas has led to the search for accurate biomarkers at the molecular level. Follicular thyroid carcinoma (FTC) is a typical example of differentiated thyroid carcinomas (DTC) in which challenges are faced in the differential diagnosis. METHODS:We used high-throughp...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-017-3948-3

    authors: Celestino R,Nome T,Pestana A,Hoff AM,Gonçalves AP,Pereira L,Cavadas B,Eloy C,Bjøro T,Sobrinho-Simões M,Skotheim RI,Soares P

    更新日期:2018-01-10 00:00:00

  • Ethnic and socioeconomic trends in breast cancer incidence in New Zealand.

    abstract:BACKGROUND:Breast cancer incidence varies between social groups, but differences have not been thoroughly examined in New Zealand. The objectives of this study are to determine whether trends in breast cancer incidence varied by ethnicity and socioeconomic position between 1981 and 2004 in New Zealand, and to assess po...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-10-674

    authors: Cunningham R,Shaw C,Blakely T,Atkinson J,Sarfati D

    更新日期:2010-12-07 00:00:00

  • Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer.

    abstract:BACKGROUND:Renal cell carcinoma (RCC) is a malignant disease that demonstrates resistance to standard chemotherapeutic agents. Yet Active immunization using genetically modified dendritic cells holds promise for the adjuvant treatment of malignancies to eradicate or control residual disease. Cytokine-induced killer (CI...

    journal_title:BMC cancer

    pub_type: 临床试验,杂志文章

    doi:10.1186/1471-2407-14-251

    authors: Wang D,Zhang B,Gao H,Ding G,Wu Q,Zhang J,Liao L,Chen H

    更新日期:2014-04-10 00:00:00

  • Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.

    abstract:BACKGROUND:The enhancer of zeste homolog 2 (EZH2) gene exerts oncogene-like activities and its (over)expression has been linked to several human malignancies. Here, we studied a possible association between EZH2 expression and prognosis in patients with renal cell carcinoma (RCC). METHODS:EZH2 protein expression in RC...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-10-524

    authors: Wagener N,Macher-Goeppinger S,Pritsch M,Hüsing J,Hoppe-Seyler K,Schirmacher P,Pfitzenmaier J,Haferkamp A,Hoppe-Seyler F,Hohenfellner M

    更新日期:2010-10-04 00:00:00

  • Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.

    abstract:BACKGROUND:This study aimed to investigate the clinical utility of serum and histological MMP-9 detection during neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC). METHODS:A total of 303 TNBC patients who underwent weekly paclitaxel plus carboplatin treatments followed by surgical resection were ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-018-4822-7

    authors: Wang RX,Chen S,Huang L,Shao ZM

    更新日期:2018-09-21 00:00:00

  • High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.

    abstract:BACKGROUND:Several lines of evidence indicate that Sirt1, a class III histone deacetylase (HDAC) is implicated in the initiation and progression of malignancies and thus gained attraction as druggable target. Since data on the role of Sirt1 in pancreatic ductal adenocarcinoma (PDAC) are sparse, we investigated the expr...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-13-450

    authors: Stenzinger A,Endris V,Klauschen F,Sinn B,Lorenz K,Warth A,Goeppert B,Ehemann V,Muckenhuber A,Kamphues C,Bahra M,Neuhaus P,Weichert W

    更新日期:2013-10-02 00:00:00

  • The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients.

    abstract:BACKGROUND:CD133 (prominin-1) is widely believed to be a cancer stem cell marker in various solid tumor types, and CD133 has been correlated with tumor-initiating capacity. Recently, the nuclear location of CD133 expression in tumors has been discussed, but hepatocellular carcinoma (HCC) has not been included in these ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-017-3460-9

    authors: Chen YL,Lin PY,Ming YZ,Huang WC,Chen RF,Chen PM,Chu PY

    更新日期:2017-07-07 00:00:00

  • A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease.

    abstract:BACKGROUND:Triple-negative breast cancer (TNBC) exhibit characteristics quite distinct from other kinds of breast cancer, presenting as an aggressive disease--recurring and metastasizing more often than other kinds of breast cancer, without tumor-specific treatment options and accounts for 15% of all types of breast ca...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-12-120

    authors: Kaur P,Nagaraja GM,Zheng H,Gizachew D,Galukande M,Krishnan S,Asea A

    更新日期:2012-03-27 00:00:00

  • Association between cigarette smoking, APC mutations and the risk of developing sporadic colorectal adenomas and carcinomas.

    abstract:BACKGROUND:The association between colorectal cancer (CRC) and smoking has not been consistent. Incomplete smoking history and association to a specific subset of CRC tumors have been proposed as explanations. The adenomatous polyposis coli (APC) gene has been reported to have a "gatekeeper" function in the colonic muc...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-6-71

    authors: Sarebø M,Skjelbred CF,Breistein R,Lothe IM,Hagen PC,Bock G,Hansteen IL,Kure EH

    更新日期:2006-03-17 00:00:00

  • A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio.

    abstract:BACKGROUND:Plenty of studies have demonstrated the prognostic value of various inflammation-based indexes in cancer. This study was designed to investigate the prognostic value of the C-reactive protein/albumin (CRP/Alb) ratio in esophageal squamous cell carcinoma. METHODS:A retrospective study of 423 cases with newly...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-015-1379-6

    authors: Wei XL,Wang FH,Zhang DS,Qiu MZ,Ren C,Jin Y,Zhou YX,Wang DS,He MM,Bai L,Wang F,Luo HY,Li YH,Xu RH

    更新日期:2015-05-02 00:00:00

  • Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.

    abstract:BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related death in the world with a five-year survival rate of less than 5%. Not all PDAC are the same, because there exist intra-tumoral heterogeneity between PDAC, which poses a great challenge to personalized treatments for PDAC. ...

    journal_title:BMC cancer

    pub_type: 杂志文章,meta分析

    doi:10.1186/s12885-018-4546-8

    authors: Zhao L,Zhao H,Yan H

    更新日期:2018-05-29 00:00:00

  • Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy.

    abstract:BACKGROUND:To compare the survival outcomes and acute toxicities of concurrent chemoradiotherapy (CCRT), induction chemotherapy (IC) plus radiotherapy (RT), and IC plus CCRT in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated using intensity-modulated radiotherapy (IMRT). METHODS:Patients w...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-015-1768-x

    authors: Li WF,Li YQ,Chen L,Zhang Y,Guo R,Zhang F,Peng H,Sun Y,Ma J

    更新日期:2015-10-27 00:00:00

  • Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.

    abstract:BACKGROUND:Recent large trials have shown the survival benefits of 10-year use of tamoxifen by reducing late recurrence compared with 5-year therapy in estrogen receptor(ER)-positive breast cancer. We tried to identify clinical factors associated with the late recurrence. METHODS:We reviewed our database of ER-positiv...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2423-x

    authors: Lee ES,Han W,Kim MK,Kim J,Yoo TK,Lee MH,Lee KH,Kim TY,Moon HG,Im SA,Noh DY,Lee ES

    更新日期:2016-07-07 00:00:00

  • Cancer incidence and mortality in Serbia 1999-2009.

    abstract:BACKGROUND:Despite the increase in cancer incidence in the last years in Serbia, no nation-wide, population-based cancer epidemiology data have been reported. In this study cancer incidence and mortality rates for Serbia are presented using nation-wide data from two population-based cancer registries. These rates are a...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-13-18

    authors: Mihajlović J,Pechlivanoglou P,Miladinov-Mikov M,Zivković S,Postma MJ

    更新日期:2013-01-15 00:00:00

  • SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial.

    abstract:BACKGROUND:Retrospective studies show improved outcomes in colorectal cancer patients if taking statins, including overall survival, pathological response of rectal cancer to preoperative chemoradiotherapy (pCRT), and reduced acute and late toxicities of pelvic radiation. Major tumour regression following pCRT has stro...

    journal_title:BMC cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/s12885-019-6405-7

    authors: Jameson MB,Gormly K,Espinoza D,Hague W,Asghari G,Jeffery GM,Price TJ,Karapetis CS,Arendse M,Armstrong J,Childs J,Frizelle FA,Ngan S,Stevenson A,Oostendorp M,Ackland SP

    更新日期:2019-12-17 00:00:00

  • Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.

    abstract:BACKGROUND:Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell-free plasma KRAS (cfKRASmut) and CA 19-9 during adjuvant treatment and follow-...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-020-07736-x

    authors: Hussung S,Akhoundova D,Hipp J,Follo M,Klar RFU,Philipp U,Scherer F,von Bubnoff N,Duyster J,Boerries M,Wittel U,Fritsch RM

    更新日期:2021-01-11 00:00:00

  • Assessing pathogenicity of MLH1 variants by co-expression of human MLH1 and PMS2 genes in yeast.

    abstract:BACKGROUND:Loss of DNA mismatch repair (MMR) in humans, mainly due to mutations in the hMLH1 gene, is linked to hereditary nonpolyposis colorectal cancer (HNPCC). Because not all MLH1 alterations result in loss of MMR function, accurate characterization of variants and their classification in terms of their effect on M...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-9-382

    authors: Vogelsang M,Comino A,Zupanec N,Hudler P,Komel R

    更新日期:2009-10-28 00:00:00

  • Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells.

    abstract:BACKGROUND:For most patients, pancreatic adenocarcinoma responds poorly to treatment, and novel therapeutic approaches are needed. Standard-of-care paclitaxel (PTX), combined with birinapant (BRP), a bivalent mimetic of the apoptosis antagonist SMAC (second mitochondria-derived activator of caspases), exerts synergisti...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-020-07398-9

    authors: Niu J,Wang X,Qu J,Mager DE,Straubinger RM

    更新日期:2020-10-23 00:00:00

  • Lentivirus-mediated CDglyTK gene-modified free flaps by intra-artery perfusion show targeted therapeutic efficacy in rat model of breast cancer.

    abstract:BACKGROUND:Free flap-mediated gene therapy in the tumor bed following surgical resection is a promising approach in cancer targeted treatment of residual disease. We investigated the selective killing efficacy of a lentivirus-mediated cytosine deaminase-thymidine kinase (CDglyTK) gene in transplanted breast cancer deli...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-019-6111-5

    authors: Zhang J,Liu Y,Zang M,Zhu S,Chen B,Li S,Xue B,Yan L

    更新日期:2019-09-14 00:00:00

  • An immunochemistry-based screen for chemical inhibitors of DNA-protein interactions and its application to human CGGBP1.

    abstract:BACKGROUND:Inhibition of DNA-binding of proteins by small-molecule chemicals holds immense potential in manipulating the activities of DNA-binding proteins. Such a chemical inhibition of DNA-binding of proteins can be used to modulate processes such as replication, transcription, DNA repair and maintenance of epigeneti...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-020-07526-5

    authors: Patel M,Patel D,Datta S,Singh U

    更新日期:2020-10-20 00:00:00